1. Current progress in clinical, molecular, and genetic aspects of adult fibromuscular dysplasia.
- Author
-
Persu A, Dobrowolski P, Gornik HL, Olin JW, Adlam D, Azizi M, Boutouyrie P, Bruno RM, Boulanger M, Demoulin JB, Ganesh SK, J Guzik T, Januszewicz M, Kovacic JC, Kruk M, de Leeuw P, Loeys BL, Pappaccogli M, Perik MHAM, Touzé E, Van der Niepen P, Van Twist DJL, Warchoł-Celińska E, Prejbisz A, and Januszewicz A
- Subjects
- Animals, Gene Expression Profiling trends, Genetic Predisposition to Disease, Hemodynamics, Humans, Phenotype, Predictive Value of Tests, Prognosis, Proteomics trends, Risk Assessment, Risk Factors, Vascular Remodeling, Arteries metabolism, Arteries pathology, Arteries physiopathology, Biomedical Research trends, Fibromuscular Dysplasia diagnosis, Fibromuscular Dysplasia genetics, Fibromuscular Dysplasia metabolism, Fibromuscular Dysplasia physiopathology, Molecular Diagnostic Techniques trends
- Abstract
Fibromuscular dysplasia (FMD) is a non-atherosclerotic vascular disease that may involve medium-sized muscular arteries throughout the body. The majority of FMD patients are women. Although a variety of genetic, mechanical, and hormonal factors play a role in the pathogenesis of FMD, overall, its cause remains poorly understood. It is probable that the pathogenesis of FMD is linked to a combination of genetic and environmental factors. Extensive studies have correlated the arterial lesions of FMD to histopathological findings of arterial fibrosis, cellular hyperplasia, and distortion of the abnormal architecture of the arterial wall. More recently, the vascular phenotype of lesions associated with FMD has been expanded to include arterial aneurysms, dissections, and tortuosity. However, in the absence of a string-of-beads or focal stenosis, these lesions do not suffice to establish the diagnosis. While FMD most commonly involves renal and cerebrovascular arteries, involvement of most arteries throughout the body has been reported. Increasing evidence highlights that FMD is a systemic arterial disease and that subclinical alterations can be found in non-affected arterial segments. Recent significant progress in FMD-related research has led to improve our understanding of the disease's clinical manifestations, natural history, epidemiology, and genetics. Ongoing work continues to focus on FMD genetics and proteomics, physiological effects of FMD on cardiovascular structure and function, and novel imaging modalities and blood-based biomarkers that can be used to identify subclinical FMD. It is also hoped that the next decade will bring the development of multi-centred and potentially international clinical trials to provide comparative effectiveness data to inform the optimal management of patients with FMD., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF